Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NZK7

UPID:
PA2GE_HUMAN

ALTERNATIVE NAMES:
Phosphatidylcholine 2-acylhydrolase 2E

ALTERNATIVE UPACC:
Q9NZK7; Q5VXJ8

BACKGROUND:
The enzyme Group IIE secretory phospholipase A2, with its alternative name Phosphatidylcholine 2-acylhydrolase 2E, is key in hydrolyzing phospholipids to release fatty acids and lysophosphatidylethanolamines. It plays a significant role in lipid remodeling of cellular membranes and the generation of lipid mediators for pathogen clearance. Additionally, it regulates hair follicle homeostasis and the inflammatory response by releasing key lipid mediators.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Group IIE secretory phospholipase A2 offers a promising avenue for developing novel therapeutic approaches. Its critical role in lipid metabolism, membrane remodeling, and inflammation presents it as a valuable target for drug discovery in addressing metabolic and inflammatory conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.